JP2016108250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016108250A5 JP2016108250A5 JP2014244421A JP2014244421A JP2016108250A5 JP 2016108250 A5 JP2016108250 A5 JP 2016108250A5 JP 2014244421 A JP2014244421 A JP 2014244421A JP 2014244421 A JP2014244421 A JP 2014244421A JP 2016108250 A5 JP2016108250 A5 JP 2016108250A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- stranded nucleic
- composition according
- adjuvant composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014244421A JP6453063B2 (ja) | 2014-12-02 | 2014-12-02 | アジュバント組成物 |
| CA2969024A CA2969024C (en) | 2014-12-02 | 2015-12-01 | Adjuvant composition |
| PCT/JP2015/083825 WO2016088784A1 (ja) | 2014-12-02 | 2015-12-01 | アジュバント組成物 |
| CN201580065778.3A CN106999573B (zh) | 2014-12-02 | 2015-12-01 | 佐剂组合物 |
| AU2015356078A AU2015356078B2 (en) | 2014-12-02 | 2015-12-01 | Adjuvant composition |
| EP15865520.9A EP3228322B8 (en) | 2014-12-02 | 2015-12-01 | Adjuvant composition |
| US15/531,671 US10105385B1 (en) | 2014-12-02 | 2015-12-01 | Adjuvant composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014244421A JP6453063B2 (ja) | 2014-12-02 | 2014-12-02 | アジュバント組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016108250A JP2016108250A (ja) | 2016-06-20 |
| JP2016108250A5 true JP2016108250A5 (enExample) | 2018-01-25 |
| JP6453063B2 JP6453063B2 (ja) | 2019-01-16 |
Family
ID=56091725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014244421A Active JP6453063B2 (ja) | 2014-12-02 | 2014-12-02 | アジュバント組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10105385B1 (enExample) |
| EP (1) | EP3228322B8 (enExample) |
| JP (1) | JP6453063B2 (enExample) |
| CN (1) | CN106999573B (enExample) |
| AU (1) | AU2015356078B2 (enExample) |
| CA (1) | CA2969024C (enExample) |
| WO (1) | WO2016088784A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11020473B2 (en) * | 2016-06-24 | 2021-06-01 | Institut Pasteur | Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases |
| KR20190034210A (ko) | 2016-07-27 | 2019-04-01 | 가부시키가이샤 츠기츠기세다이 이노베이숀 가이하츠 | 암 면역 아쥬반트 |
| US11583575B2 (en) | 2016-09-06 | 2023-02-21 | Roche Sequencing Solutions, Inc. | MHC-bound peptide arrays and methods of use thereof |
| CN120265778A (zh) | 2022-12-05 | 2025-07-04 | 学校法人青森山田学园 | 核酸佐剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2323927A1 (en) * | 1998-03-26 | 1999-09-30 | American Cyanamid Company | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b |
| JPWO2008065752A1 (ja) * | 2006-11-30 | 2010-03-04 | 国立大学法人北海道大学 | ｄｉＲＮＡを有効成分とする免疫治療用薬剤 |
| EP2085479A1 (en) * | 2008-01-31 | 2009-08-05 | Institut Pasteur | Reverse genetics of negative-strand rna viruses in yeast |
| EP3269811B1 (en) * | 2010-07-28 | 2020-10-07 | Advanced Innovation Development Co. Ltd. | Nucleic acid having adjuvant activity and use thereof |
| CN102000330B (zh) * | 2010-09-14 | 2012-08-29 | 中国人民解放军第二军医大学 | 一种核酸疫苗佐剂及其构建方法 |
-
2014
- 2014-12-02 JP JP2014244421A patent/JP6453063B2/ja active Active
-
2015
- 2015-12-01 EP EP15865520.9A patent/EP3228322B8/en active Active
- 2015-12-01 CN CN201580065778.3A patent/CN106999573B/zh active Active
- 2015-12-01 US US15/531,671 patent/US10105385B1/en active Active
- 2015-12-01 CA CA2969024A patent/CA2969024C/en active Active
- 2015-12-01 AU AU2015356078A patent/AU2015356078B2/en active Active
- 2015-12-01 WO PCT/JP2015/083825 patent/WO2016088784A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526529A5 (enExample) | ||
| JP2016525888A5 (enExample) | ||
| EP4501318A3 (en) | Nucleic acid vaccines | |
| CN111741967A (zh) | 核苷类似物、制备方法及应用 | |
| JP2016528887A5 (enExample) | ||
| JP2016195614A5 (enExample) | ||
| EP4328322A3 (en) | Probe library construction | |
| JP2017502668A5 (enExample) | ||
| WO2015196128A3 (en) | Alternative nucleic acid molecules and uses thereof | |
| WO2015196130A3 (en) | Alternative nucleic acid molecules and uses thereof | |
| JP2019515674A5 (enExample) | ||
| JP2018518163A5 (enExample) | ||
| JP2015133993A5 (enExample) | ||
| WO2015081229A3 (en) | Selective amplification of nucleic acid sequences | |
| EP4310196A3 (en) | Methods and compositions for manipulating nucleic acids | |
| JP2013005803A5 (enExample) | ||
| IL250539A0 (en) | Nucleotides modified for nucleic acid synthesis, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes | |
| WO2015089511A3 (en) | Modified nucleic acid molecules and uses thereof | |
| WO2017015463A3 (en) | Infectious disease vaccines | |
| JP2018512041A5 (enExample) | ||
| JP2016513950A5 (enExample) | ||
| HK1245800A1 (zh) | 被取代的核苷、核苷酸及其类似物 | |
| HK1203513A1 (en) | Methods of preparing substituted nucleotide analogs | |
| BR112015022522A2 (pt) | engenharia de genomas de planta usando sistemas crispr/cas | |
| WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |